Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner

Oren Gilad¹, Barzin Y. Nabet¹, Ryan L. Ragland¹, David W. Schoppy¹, Kevin D. Smith¹, Amy C. Durham², and Eric J. Brown¹

Abstract

Previous studies indicate that oncogenic stress activates the ATR-Chk1 pathway. Here, we show that ATR-Chk1 pathway engagement is essential for limiting genomic instability following oncogenic Ras transformation. ATR pathway inhibition in combination with oncogenic Ras expression synergistically increased genomic instability, as quantified by chromatid breaks, sister chromatid exchanges, and H2AX phosphorylation. This level of instability was significantly greater than that observed following ATR suppression in untransformed control cells. In addition, consistent with a deficiency in long-term genome maintenance, hypomorphic ATR pathway reduction to 16% of normal levels was synthetic lethal with oncogenic Ras expression in cultured cells. Notably, elevated genomic instability and synthetic lethality following suppression of ATR were not due to accelerated cycling rates in Ras-transformed cells, indicating that these synergistic effects were generated on a per-cell-cycle basis. In contrast to the synthetic lethal effects of hypomorphic ATR suppression, subtle reduction of ATR expression (haploinsufficiency) in combination with endogenous levels of K-rasG12D expression elevated the incidence of lung adenocarcinoma, spindle cell sarcoma, and thymic lymphoma in p53 heterozygous mice. K-rasG12D-induced tumorigenesis in ATR⁺/⁻/C₀ p53⁺/⁻/C₀ mice was associated with intrachromosomal deletions and loss of wild-type p53. These findings indicate that synergistic increases in genomic instability following ATR reduction in oncogenic Ras-transformed cells can produce 2 distinct biological outcomes: synthetic lethality upon significant suppression of ATR expression and tumor promotion in the context of ATR haploinsufficiency. These results highlight the importance of the ATR pathway both as a barrier to malignant progression and as a potential target for cancer treatment.

Introduction

Hyperproliferative stimuli, oncogenic stress, and tumor progression are associated with elevated genomic instability and DNA damage checkpoint signaling (1–8). Checkpoint signaling is regulated in large part by the ATR and ATM protein kinases, which serve as initial responders to aberrant replication fork progression and DNA double-strand breaks, respectively (9, 10). Checkpoint activation in these contexts has been proposed to function as a barrier to malignant progression by both preventing proliferation and countering the untoward effects of oncogenic stress on DNA metabolism and integrity (2, 3, 8).

Activation of the ATR pathway by oncogenic stress has been attributed to a variety of cellular changes, including premature or redundant origin firing, changes in interorigin distance, and increased oxidative DNA damage (4–12). In both yeast and vertebrates, ATR signaling plays a critical role in maintaining genome stability following irregularities in DNA replication fork progression. Inhibition of polymerase processivity (e.g., reduced catalysis or encounters with damaged bases) and other disruptions that uncouple DNA unwinding from nucleotide incorporation activate ATR, which prevents replication fork collapse into DNA double-strand breaks (9, 10, 13–22). In accordance with this function, chromatid breaks at common fragile sites and other difficult-to-replicate regions of the genome are particularly increased when partial polymerase inhibition is combined with suppression of the ATR-Chk1 pathway (9, 17–19, 23). Notably, oncogenic stress alone has also been shown to increase breakage at common fragile sites (2, 3, 8), implying that suppression of the ATR-Chk1 pathway in this context may further elevate genomic instability in a synergistic fashion.
Herein, we investigate the hypothesis that oncogenic transformation produces an increased reliance on the ATR-Chk1 pathway to maintain genome stability. We show that ATR-Chk1 pathway inhibition in combination with expression of oncogenic forms of Ras elevates double-strand break formation and mitotic recombination on a per-cell-cycle basis. Importantly, oncogene-induced dependence on the ATR pathway to maintain genome stability leads to distinct effects following ATR suppression: either promoting oncogenic Ras-induced tumorigenesis when ATR is haploinsufficient or causing synthetic lethality when the ATR-Chk1 pathway is inhibited more substantially. These results show the importance of the ATR-Chk1 pathway in maintaining genomic stability under oncogenic stress and imply a key role for ATR suppression in both cancer etiology and treatment.

Materials and Methods

Oncogenic Ras-transformed cell line generation

Murine embryonic fibroblasts (MEFs) were immortalized via lentiviral introduction of shRNAs targeting p16⁰NκRA⁰ and p19⁰ARF⁰ (TRCN0000077813). Oncogenic Ras was expressed either 1) by the treatment of K-ras⁰G12D⁰/⁰-Cre-ERT²⁰ MEFs with 0.2 μmol/L of 4-hydroxytamoxifen (4-OHT; Calbiochem) for 48 hours (K-ras⁰G12D⁰/⁰ endogenous levels) or 2) by infection of NIH3T3 cells (clone 7) or immortalized MEFs with recombinant retrovirus expressing K-ras⁰G12D⁰ or H-ras⁰G12V⁰. Control cell lines were produced in parallel using retrovirus derived from the corresponding empty vectors (pWZL-hygro or pBABE-puro vectors) or 200 μmol/L of puromycin (pBABE-puro vectors) or 200 μg/mL of hygromycin (pWZL-hygro vectors) for 4 to 7 days to enrich the transduced cells.

Cell culture and lentiviral infections

For all experiments, cells were cultured in defined growth media [DMEM supplemented with bovine pancreatic insulin (10 μg/mL, Sigma), transferrin (10 μg/mL, Calbiochem), HEPES (10 μg/mL, Lee Biosolutions), recombinant murine EGF (50 ng/mL, Millipore), glutamine (2 mmol/L, Gibco), 10% fetal bovine serum (FBS, Hyclone)] similar to previously described conditions (24, 25). For p53 allele quantification, primer and probe sets detected the wild-type or mutant p53 alleles (Supplemental Table S1) were designed using the Primer3Plus program for regional quantification of chromosome 11 (Supplemental Table S1) were designed using the Primer3Plus program. Noted pathologies were tracked across nearby stained sections (50-μm apart) and quantified per lung by double-blind methods. Immunohistochemical detection of p53 was carried out on fixed tumor samples following antigen unmasking in 10.9 mmol/L of citric acid and inactivation of endogenous peroxidases with hydrogen peroxide. Incubation with anti-p53 antibodies (Novocastra; NCL-p53-CM5p, 1:100, 1 hour at room temperature) and 3,3′-diaminobenzidine staining. Slides were washed and stained for 2 minutes with hematoxylin before mounting and visualization.

Mitotic spreads and detection of chromatid breaks and sister chromatid exchange

Mitotic spreads were prepared as previously described following a 3- to 4-hour treatment with 0.5 μmol/L of nocodazole (19, 21). To detect and quantify sister chromatid exchanges (SCEs), cells were incubated with 10 μmol/L of BrdU (Sigma) for 2 cell doublings and subsequently arrested in mitosis via nocodazole treatment. Mitotic spreads were prepared, processed, stained with Giemsa, and photographed using a 100× objective lens. Quantification of chromatid breaks and SCEs were performed using double-blind methods.

Tumorogenesis in LSL-K-ras⁰G12D⁰ mice and histologic analysis

LSL-K-ras⁰G12D⁰ (26, 27), Cre-ERT²⁺ (28), p53⁻¹⁻/- (tm1Tyj) and ATR⁻/⁻ (13) mice were intercrossed to produce the indicated genotypes (background: 129Sve/C57BL/6 mixed). Tamoxifen (20 mg/mL in 98% corn oil:2% ethanol) was administered via a single intraperitoneal injection at a dose of 0.3 mg (15 μl). Mice were monitored until death or when euthanized in accordance with IACUC endpoint criteria. Following necropsy, tissues were fixed in 4% paraformaldehyde in phosphate buffered saline at 4°C overnight, dehydrated, and embedded in paraffin. For gross histologic examination of lung tissue, 5-μm serial sections were generated and the 10th section of each series was mounted and stained with hematoxylin and eosin (H&E) for histopathologic evaluation. Classification of pulmonary lesions was performed as described (29). Noted pathologies were tracked across nearby stained sections (50-μm apart) and quantified per lung by double-blind methods. Immunohistochemical detection of p53 was carried out on fixed tumor samples following antigen unmasking in 10.9 mmol/L of citric acid and inactivation of endogenous peroxidases with hydrogen peroxide. Incubation with anti-p53 antibodies (Novocastra; NCL-p53-CM5p, 1:100, 4°C overnight) was followed by detection with goat anti-rabbit (1:100) HRP-conjugated secondary antibodies (1 hour at room temperature) and 3,3′-diaminobenzidine staining. Slides were washed and stained for 2 minutes with hematoxylin before mounting and visualization.

Quantitative PCR

Applied Biosystems Primer Express Software 3.0 was utilized for design of quantitative PCR (qPCR) primer and minor groove binder probe sets to detect the wild-type p53 and unrecombined LSL-K-ras⁰G12D⁰ alleles (Supplementary Table 1). For p53 allele quantification, primer and probe sets detected intrinsic sequences between exons 6 and 7 of wild-type p53, a region deleted within the p53-null allele. For detection of mosaic lox recombination of the LSL-K-ras⁰G12D⁰ allele, primer and probe sets (26) were used to amplify and detect sequences in the transcriptional stop element and flanking a single lox P site. qPCR was carried out with genomic DNA as a template; amplification and detection were carried out using TaqMan Universal PCR Master Mix (Applied Biosystems) on an Applied Biosystems 7900HT sequence detection system. Primer sets for regional quantification of chromosome 11 (Supplemental Table S1) were designed using the Primer3Plus program (UCSC), and qPCR of tumor and tail genomic DNA was carried
out using SYBR Green PCR Master Mix (Applied Biosystems). Amplification of GAPDH was used as an endogenous control for all ΔΔCT analyses.

Array-based comparative genomic hybridization

Mouse comparative genomic hybridization (CGH) microarrays (180,000 oligos per array, 4 arrays per chip; Agilent Technologies) were custom designed using eArray software (Agilent Technologies), with genomic regions represented at 500-bp intervals within the p53 locus and at 50-kb intervals throughout the remainder of the mouse genome. Genomic DNA from tumor and tamoxifen-untreated tail tissue was utilized for fluorescent probe generation (500 ng of DNA per probe). Reciprocal labeling and hybridization of tumor and normal DNA on 2 independent arrays per tumor sample were carried out (dye-swap) using Cy3 and Cy5 fluorophors. Arrays were scanned with Agilent Scanner Control software following manufacturer’s instructions (Agilent Technologies). Scanned images from CGH 2-color oligonucleotide arrays were analyzed using the Partek Genomics Suite (Version 6.5; Partek Inc.).

Results

Oncogenic Ras transformation creates an increased reliance on the ATR-Chk1 pathway to maintain genome integrity

Engagement of the ATR-Chk1 pathway maintains genome stability in response to irregularities in the progression of DNA replication (9, 13–22). Because hyperactive growth factor signaling and oncogenic stress have each been shown to activate the ATR-Chk1 pathway in human cells (2–7), we hypothesized that ATR-Chk1 activation under these conditions may provide an important genome-stabilizing function. To examine the effect of ATR-Chk1 pathway inhibition in combination with oncogene transformation, mouse embryonic fibroblast cell lines expressing K-rasG12D or H-rasG12V were generated. Ras expression led to phenotypes characteristic of transformation, including increased ERK phosphorylation, morphologic changes, loss of contact inhibition at confluence, and the ability to produce tumors following transplantation into immunocompromised mice (data not shown).

The ability of oncogenic Ras expression to activate the ATR-Chk1 pathway in murine cells was confirmed by quantification of Chk1 phosphorylation on S345, an ATR kinase substrate. These studies were carried out under defined growth factor conditions that have been previously shown to ameliorate the genome destabilizing effects of cell culture and, in subconfluent cultures, cause cell cycling rates to be similar between pressed, H-rasG12V-transformed cells and untransformed controls was similar to that stimulated by the treatment of control cells with 0.23 μmol/L of aphidicolin (Fig. 1B and C), a concentration of DNA polymerase inhibitor that only partially impedes nucleotide incorporation (18). In aggregate, these studies show that oncogenic Ras activates the ATR pathway in a manner that is compatible with continued DNA synthesis and is not the product of increased S-phase representation or accelerated proliferation rates (Figs. 1 and 3A). Irregularities in DNA synthesis have been previously shown to cause an increased reliance on the ATR pathway to suppress double-strand break generation (9, 18, 19, 21, 22). We reasoned that H-rasG12V—transformation might similarly create a dependence on ATR-Chk1 pathway activation to maintain genome integrity. To test this hypothesis, the effect of inhibiting the ATR-Chk1 pathway on genome integrity in H-rasG12V-transformed cells and untransformed controls was quantified using 3 hallmarks of genomic instability: H2AX phosphorylation, SCE, and chromatid breaks.

ATR deficiency in combination with exogenous DNA polymerase inhibition (e.g., aphidicolin treatment) has previously been shown to stimulate ATM/DNA-PK–dependent phosphorylation of H2AX in response to increased double-strand break formation (19, 21). Similarly, ATR/Chk1 pathway inhibition in H-rasG12V-expressing cells elevated H2AX phosphorylation to significantly higher levels than in control cells (Fig. 2A). Such synergistic increases were observed using hypomorphic suppression of ATR expression to 15.7% of normal levels (+3.8% standard error (SE)) and following short-term inhibition of Chk1 kinase activity (3-hour G66976 treatment; Fig. 2A). These greater than additive increases in H2AX phosphorylation were observed in multiple independent Ras-transformed cell lines following ATR suppression (data not shown). Therefore, H-rasG12V expression increases reliance on the ATR-Chk1 pathway to prevent H2AX phosphorylation during otherwise unperturbed cell-cycle progression.

Consistent with an increase in double-strand breaks and subsequent recombinatorial repair, SCE rates in ATR-suppressed, H-rasG12V—transformed cells were significantly elevated over those observed in control cells (Fig. 2B and D). Importantly, because the SCE staining procedure measures recombination frequencies precisely within 2 consecutive rounds of replication, increased SCE rates in oncogenic Ras-transformed cells cannot be due to elevated representation of S-phase or increased cell-cycling rates. The ability of short-term Chk1 inhibition to induce H2AX phosphorylation in Ras-transformed cells (Fig. 2A) is consistent with this interpretation. These findings indicate that ATR-Chk1 pathway inhibition in combination with oncogenic stress leads to an increased utilization of DNA repair responses and that such
elevated rates of recombination are manifested within the context of individual cell cycles.

We next examined whether the combination of ATR suppression with oncogenic stress was sufficient to overwhelm compensatory DNA repair responses (Fig. 2A and B) and lead to increased chromatid breaks in M phase. Chromosome spreads were collected from H-rasG12V-transformed and control cells after shRNA-mediated ATR suppression. Remarkably, suppressed expression of ATR in oncogenic Ras-transformed cells led to a highly synergistic increase in chromatid breaks over that observed in control cells (Fig. 2C and D). This synergistic effect may be produced both by elevated double-strand break formation (Fig. 2A) and by cell-cycle checkpoint deficiency, which allows increased transmission of breaks into M phase (19). Similar increases in chromosome breaks were observed using a distinct shRNA that targets ATR (Supplementary Fig. 2A and B). Notably, a portion of these breaks was observed at the Fra14A2 and Fra8E1 common fragile sites (FHIT and WWOX, respectively; data not shown), consistent with activation of the ATR pathway serving an important role in suppressing common fragile site breakage under oncogenic stress. In aggregate, these data show that ATR pathway activation is relied upon to maintain genome stability under conditions of oncogenic stress.

Increased chromatid breaks in M phase predict several potential biological outcomes, depending on the level of ATR reduction. Because genomic instability was synergistically elevated when ATR suppression was combined with oncogenic stress (Fig. 2), significant suppression of ATR to hypomorphic levels might drive genomic instability to intolerable levels in Ras-transformed cells while leaving untransformed counterparts relatively intact. Alternatively, ATR deficiency might sufficiently compromise cell-cycle control to permit continued proliferation of Ras-transformed cells, despite increased genomic instability. Similarly, subtle reduction in ATR expression, such as haploinsufficiency, might either be sufficient to suppress tumorigenesis initiated by K-ras or accelerate malignant progression through a variety of mechanisms, including increased genomic instability and tumor suppressor gene loss. These distinct possibilities were tested.

**Hypomorphic ATR pathway suppression is synthetic lethal with oncogenic Ras expression**

As described earlier, significant reduction in ATR expression might either i) synergize with Ras-driven oncogenic stress to generate a level of genomic instability that is incompatible with continued cell proliferation (synthetic lethality) or ii)
suppress cell-cycle checkpoint control and permit the continued proliferation of genetically unstable cells. To test these hypotheses, shRNA-mediated targeting was used to reduce ATR expression to 16% of normal levels in H-rasG12V-transformed cells and untransformed controls (Figs. 2 and 3) and cell proliferation was measured. Within the first 4 days of culture, hypomorphic ATR suppression did not significantly affect the proliferation of Ras-transformed or control cells (Figs. 2 and 3) and cell proliferation was measured. Within the first 4 days of culture, hypomorphic ATR suppression did not significantly affect the proliferation of Ras-transformed or control lines (Fig. 3A and B), consistent with ineffectual cell-cycle checkpoint responses to the instability observed at day 2 (Fig. 2).

However, by 6 to 8 days, the proliferation of H-rasG12V-transformed cells was potently suppressed by reduced ATR expression, ultimately leading to diminished cell numbers (Fig. 3A). The suppressed proliferation of H-rasG12V-transformed cells was at least partly due to an increased rate of cell death, based on the elevated frequency of cells with sub-G1 DNA content (Fig. 3C and D). Importantly, although hypomorphic ATR suppression ultimately limited the proliferation of both cell types (Fig. 3A–D), the antiproliferative effect of ATR reduction on H-rasG12V-transformed cells was significantly greater than that observed on similarly treated untransformed controls (Fig. 3A, P = 0.03; Fig. 3D, P = 0.01). This selective effect was also observed using a distinct shRNA that targets ATR expression (Supplementary Fig. 2C). Notably, under these subconfluent conditions, Ras-transformed and untransformed controls proliferated similarly when wild-type levels of ATR were expressed (shCTRL-expressing cells; Fig. 3A). These data indicate that the effect of ATR suppression on proliferation of Ras-transformed cells is not simply the product of an increased number of cell cycles in the absence of full ATR expression but, rather, reflects increased instability on a per-cell-cycle basis.

ATR haploinsufficiency promotes K-rasG12D-induced tumorigenesis and p53 loss of heterozygosity

Because ATR-Chk1 activation is increased in the presence of oncogenic stress and during neoplastic transformation, it has been proposed that ATR and other DNA damage response genes may serve as barriers to oncogene-driven tumorigenesis.
Indeed, somatic mutations in ATR-Chk1 pathway components have been observed in human cancers and proposed to act as driver mutations in lung adenocarcinoma, endometrial carcinoma, and other cancers (30–37). Many of the mutations thus far characterized are predicted to result in only partial ATR-Chk1 pathway reduction (28, 30–32, 35, 37).

However, according to our findings (Figs. 2 and 3), ATR haploinsufficiency in combination with oncogenic stress might either limit tumorigenesis via synthetic lethality or promote it through a variety of mechanisms, including increased genomic instability and accelerated tumor suppressor gene loss.

To test the effect of haploinsufficient ATR expression (13) on oncogene-induced tumorigenesis, K-ras G12D expression was induced to endogenous levels in wild-type, ATR+/−/C0, p53+/−/C0, and ATR+/−/C0 p53+/−/C0 mice (Fig. 4A). Induction of K-rasG12D was accomplished by mosaic lox recombination of LSL-K-rasG12D knock-in allele (27) in a broad range of tissues through tamoxifen-mediated activation of a ubiquitously expressed Cre-ERT2 fusion protein (28). Using this method, recombination of the lox-stop-lox element of K-rasG12D knock-in allele ranged from 10% to 23% in analyzed tissues, as determined by qPCR on genomic DNA, and was not significantly affected by ATR haploinsufficiency (Fig. 4B).

Mouse survival following K-rasG12D expression was predominantly limited by oral papillomas, which forced euthanasia due to decreased food intake, and by myeloproliferation (Fig. 4C and Supplementary Fig. 3). These previously noted phenotypes (38–40) were not affected by either ATR or p53 haploinsufficiency, leading to similar median survival times for the genotypes analyzed (range, 54–81 days). However, upon necropsy, additional tumor types were revealed and found to occur at an increased frequency in ATR+/−/C0 p53+/−/C0 mice compared with p53+/−/C0 mice (Fig. 4C and D). These tumors included thymic lymphomas (CD4+, CD8+) and subcutaneous spindle cell sarcomas (Fig. 4C), each of which was greater than 0.8 cm in diameter at the time of necropsy. Moreover, a significant increase in the appearance of lung nodules was observed in ATR+/−/C0 p53+/−/C0 mice (Fig. 4C and D). K-rasG12D expression has been shown to be sufficient to stimulate the generation of lung hyperplasias and several distinct varieties of lung adenoma; however, adenocarcinomas are most strongly induced in the absence of p53 (26, 38, 41, 42). To examine the effect of ATR haploinsufficiency on incidence of these pathologies, lungs from ATR+/−/C0 p53+/−/C0 and p53+/−/C0 animals were serial sectioned and quantified for lung adenomas and adenocarcinomas. Although the incidence of several common adenoma subtypes was unchanged by ATR heterozygosity, adenocarcinomas were observed exclusively in ATR+/−/C0 p53+/−/C0 mice (Fig. 4C and D).
preneoplasia (29), were also observed in ATR<sup>+/−</sup>/p53<sup>+/−</sup> and not detected in p53<sup>+/−</sup> controls (Fig. 4E). Together, these results show that ATR haploinsufficiency can act as a modifier of K-ras<sup>G12D</sup>–induced tumorigenesis in mice.

The increased tumorigenesis in ATR<sup>+/−</sup>/p53<sup>+/−</sup> mice in comparison to p53<sup>+/−</sup> controls suggested that ATR haploinsufficiency might drive tumorigenesis through p53 loss of heterozygosity (LOH). To examine this possibility, 2 procedures were carried out: immunocytochemical detection of p53 protein (Fig. 5A) and real-time qPCR of the wild-type p53 allele on the basis of tumor incidence, oral papillomas and myelocyte hyperproliferation were not associated with p53 LOH.

However, the tumor types observed at increased incidence in ATR heterozygous animals had a relatively high frequency of p53 loss (Fig. 5B). This loss was generally characterized by intrachromosomal deletions in mouse chromosome 11 that encompassed the wild-type Trp53 locus at 69.4 Mb, as determined by array CGH and qPCR analysis (Fig. 5C and D). In aggregate, these data indicate that ATR haploinsufficiency promotes K-ras<sup>G12D</sup>–induced tumorigenesis in a manner that correlates with increased intrachromosomal deletion of the p53 tumor suppressor gene.

**Discussion**

Herein, we show that expression of oncogenic Ras in combination with ATR suppression leads to synergistic increases in genomic instability, which was not simply the consequence of increased S-phase representation or elevated cycling rates following Ras transformation but, rather, was reflective of a greater dependence on the ATR pathway on a per-cell-cycle basis (Figs. 1–3). Synergistic increases in genomic instability produced 2 distinct biological outcomes in the context of oncogenic Ras expression: synthetic lethality upon substantial reduction of ATR expression (>80%) and tumor promotion in the context of ATR haploinsufficiency. These findings indicate that although haploinsufficient loss of ATR may subtly elevate genomic instability, and thus accelerate oncogene-driven carcinogenesis, further inhibition of the ATR-Chk1 pathway can drive genomic instability to intolerable levels and suppress proliferation.

The effect of ATR haploinsufficiency in promoting K-ras<sup>G12D</sup>–induced tumorigenesis supports a growing body of evidence indicating a functional role for mutations in ATR...
Figure 5. ATR haploinsufficiency accelerates p53 LOH in K-rasG12D-induced tumors. A, detection of p53 by immunohistochemistry in representative skin papilloma (n = 2) and thymic lymphoma (n = 4) isolated from low-dose TAM-treated ATR+/− p53+/− LSL-K-rasG12D+/Cre-ERT2+ mice. Normal thymus isolated from mice 8 hours after exposure to 10-Gy ionizing radiation (IR) is shown as a positive control for p53 detection. Sections were stained in parallel using equivalent conditions. Nuclear p53 protein was not detected in spindle cell sarcomas isolated from ATR+/− p53+/− mice (n = 3; data not shown). B, detection of genomic loss of the wild-type p53 allele in tumors isolated from TAM-treated p53+/− LSL-K-rasG12D+/− Cre-ERT2− and ATR+/− p53+/− LSL-K-rasG12D+/− Cre-ERT2+ mice. qPCR analysis of genomic DNA from tumors was performed as described in the Materials and Methods section. Wild-type p53 allele representation is shown relative to homozygous wild-type levels (p53+/+). SEs (bars) were calculated from technical replicates. Tumor samples in which the wild-type p53 allele frequency was significantly reduced are indicated (red asterisks). Enrichment of K-rasG12D− expressing cells in tumor isolates was determined by qPCR of LSL-K-rasG12Dlox recombination (Supplementary Fig. 5). C, detection of intrachromosomal deletion of p53 by array CGH and qPCR analysis. Representative qPCR regional quantification (blue bars) and array-CGH analysis of chromosome 11 (magenta line) on thymic lymphoma DNA isolated from a TAM-treated ATR+/− p53+/− LSL-K-rasG12D+/Cre-ERT2+ mouse. The location of the p53 gene is indicated. D, deleted regions predicted by qPCR analysis of chromosome 11 in representative thymic lymphomas and spindle cell sarcomas from ATR+/− p53+/− LSL-K-rasG12D+/Cre-ERT2+ mice. Real-time primer sets (Supplementary Table 1) detecting chromosome 11 regions indicated in C were utilized in qPCR quantifications of tumor DNA and compared with pre-TAM treatment tail DNA. Regions that were selectively reduced in tumor DNA are shown.
pathway components in human carcinogenesis. Somatic mutations in ATR have been identified in colon, stomach, and endometrial cancers (30–32, 35) and may influence lung adenocarcinoma progression (33, 34). In addition, a variant of Rad9, a component of the ATR-Chk1 pathway (9), has been shown to be strongly associated with increased risk of non–small cell lung cancer in humans (37). Mutations within a similar region in an *Saccharomyces cerevisiae* orthologue of human Rad9 (*S. cerevisiae Ddc1*) disrupts checkpoint signaling in response to DNA damage, suggesting that the human Rad9 variant may be functionally compromised (43). Indeed, mutation or suppression of Chk1 has been noted in colon, stomach, and endometrial cancers and select B-cell lymphomas (30, 31, 35). These genetic association studies in humans are consistent with findings indicating that suppression of ATR-Chk1 pathway components promotes tumorigenesis in select tumor models (13, 44–46).

According to our studies, the stimulatory effect of ATR-Chk1 pathway haploinsufficiency on tumorigenesis may be potently influenced by the increased reliance on ATR-Chk1 function produced by oncogenic stress (Figs. 1 and 2). Along these lines, ATR-Chk1 pathway haploinsufficiency may drive tumorigenesis either through subtle alleviation of cell-cycle control or through increased genome destabilization (Fig. 2). Notably, the expected low levels of genomic instability caused by ATR haploinsufficiency seem to be sufficient to promote the complete loss of tumor suppressor genes, such as p53 (Fig. 5), which may ultimately abrogate checkpoint function more effectively than ATR haploinsufficiency alone. These findings may be useful in correlating tumor suppressor gene loss with candidate genetic modifiers in genomewide association studies of human cancers. Moreover, detection of ATR-Chk1 pathway mutations may provide relevant prognostic indicators (47) and assist in choosing effective cancer treatment strategies, which could include inhibition of the ATR-Chk1 pathway, as discussed in the following text.

Chk1 has previously been proposed to be a potential target for cancer treatment, most notably in combination with p53 deficiency (48). Indeed, Chk1 inhibitors are currently in phase I and II clinical trials for the treatment of a variety of solid and hematologic malignancies (36, 48, 49). The studies described herein support the use of ATR-Chk1 pathway inhibition in cancer therapy. Because ATR phosphorylates a variety of DNA damage response intermediates in addition to Chk1 and selective Chk1 inhibition ultimately causes ATR activation (9, 10, 50), it is not known whether ATR inhibition will be identical in efficacy to Chk1 suppression in cancer treatment. Nevertheless, each kinase plays an important role in replication fork stabilization (9, 10), which is potentially the key function required for genome maintenance in the context of oncogenic stress and other conditions. Given the deleterious effect of complete ATR-Chk1 pathway ablation on normal tissue homeostasis (28), a critical determinant of the utility of this treatment will be identifying the genetic characteristics of cancers that cause selective sensitization to partial ATR-Chk1 inhibition.

Oncogenic Ras mutations are observed frequently in human cancers and are associated with some of the currently least treatable malignancies including pancreatic, lung, ovarian, and colon cancer. Thus, ATR-Chk1 pathway inhibition may provide therapeutic opportunities for which few alternatives are available. Many of the cancers associated with expression of oncogenic Ras also harbor mutations in p53, which as mentioned earlier is reported to produce an increased sensitivity to ATR-Chk1 pathway inhibition (36, 48, 49). Along these lines, the greatest effect of ATR-Chk1 inhibition in cancer treatment may be achieved through the combined effects of these genetic interactions (e.g., p53 loss and oncogenic stress) and others, including somatic mutations within the ATR-Chk1 pathway (30–37) or other DNA damage response genes, for example, *ATM* and *H2AX* (21, 34, 42). Thus, it is conceivable that malignancies harboring such combined genetic characteristics may be prime candidates for treatments utilizing ATR-Chk1 pathway inhibition.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

We are indebted to Amma Asare, Yaroslava Ruzankina, Sara Small, Kathleen Haines, Richard Carroll, Douglas Lin, Alan Diehl, and the AFCHI Histology Core for methodologic expertise and technical assistance. We are also grateful to the following for providing essential reagents: Tyler Jacks and David Tuveson (LSL-K-ras*G12D* mice) and J. Alan Diehl and Martine Boussell (pBabe-H-ras*G12V*).

**Grant Support**

These studies were supported by the National Institute on Aging (ROI AG027376), the Abramson Family Cancer Research Institute, and the V. Foundation. O. Gilad was supported by an National Institute of Health training grant (R25CA101871). The Amy Golden Uleis memorial fund was used for the purchase of pBabe K-ras*G12V* (Addgene, Inc.).

Received 06/25/2010; revised 09/25/2010; accepted 10/12/2010; published OnlineFirst 11/23/2010.

**References**

Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner

Oren Gilad, Barzin Y. Nabet, Ryan L. Ragland, et al.

Cancer Res 2010;70:9693-9702. Published OnlineFirst November 23, 2010.

Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-10-2286

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2010/11/23/0008-5472.CAN-10-2286.DC1

Cited articles
This article cites 49 articles, 23 of which you can access for free at:
http://cancerres.aacrjournals.org/content/70/23/9693.full.html#ref-list-1

Citing articles
This article has been cited by 23 HighWire-hosted articles. Access the articles at:
/content/70/23/9693.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.